Paper36923571
AV-101, a novel inhaled dry-powder formulation of imatinib, in healthy adult participants: a phase 1 single and multiple ascending dose study.
Gillies H and 9 others. ERJ Open Res, 2023. Cited by 24 papers, by iCite.
11 sourcespapers-2026-11-12-0.1.0
Cite this record
ConductScience Library. AV-101, a novel inhaled dry-powder formulation of imatinib, in healthy adult participants: a phase 1 single and multiple ascending dose study. Papers, record 36923571. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/36923571
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- AV-101, a novel inhaled dry-powder formulation of imatinib, in healthy adult participants: a phase 1 single and multiple ascending dose study.
- PubMed
Connected records1
Records in the library's other databases whose lists name this one, each read from that database's own release: up to 20 of each kind, the most connected first.
Topics0
NLM's MeSH indexing of the paper, its major topics first.
None in this release.
Trials1
The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.
| Trial | Title | The trial lists it as | Named in the paper's record |
|---|---|---|---|
| NCT05036135 | A Study of AV-101 (Dry Powder Inhaled Imatinib) in Patients With Pulmonary Arterial Hypertension (PAH) | Derived from the trial | Yes |
Source ClinicalTrials.gov
References38
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 26210752 | Long-term safety and efficacy of imatinib in pulmonary arterial hypertension. | J Heart Lung Transplant | 2015 | https://conductscience.org/library/papers/26210752 | PubMed |
| 2 | 34002056 | Kinase drug discovery 20 years after imatinib: progress and future directions. | Nat Rev Drug Discov | 2021 | https://conductscience.org/library/papers/34002056 | PubMed |
| 3 | 34425071 | Selonsertib in adults with pulmonary arterial hypertension (ARROW): a randomised, double-blind, placebo-controlled, phase 2 trial. | Lancet Respir Med | 2022 | https://conductscience.org/library/papers/34425071 | PubMed |
| 4 | 31709514 | Kinases as potential targets for treatment of pulmonary hypertension and right ventricular dysfunction. | Br J Pharmacol | 2021 | https://conductscience.org/library/papers/31709514 | PubMed |
| 5 | 21471108 | C-kit-positive cells accumulate in remodeled vessels of idiopathic pulmonary arterial hypertension. | Am J Respir Crit Care Med | 2011 | https://conductscience.org/library/papers/21471108 | PubMed |
| 6 | 29280349 | Translational model to predict pulmonary pharmacokinetics and efficacy in man for inhaled bronchodilators. | CPT Pharmacometrics Syst Pharmacol | 2018 | https://conductscience.org/library/papers/29280349 | PubMed |
| 7 | 27286723 | A Comprehensive Review of Treprostinil Pharmacokinetics via Four Routes of Administration. | Clin Pharmacokinet | 2016 | https://conductscience.org/library/papers/27286723 | PubMed |
| 8 | 31339889 | Nintedanib ameliorates experimental pulmonary arterial hypertension via inhibition of endothelial mesenchymal transition and smooth muscle cell proliferation. | PLoS One | 2019 | https://conductscience.org/library/papers/31339889 | PubMed |
| 9 | 24963404 | Imatinib: a breakthrough of targeted therapy in cancer. | Chemother Res Pract | 2014 | https://conductscience.org/library/papers/24963404 | PubMed |
| 10 | 20010555 | A dosing/cross-development study of the multikinase inhibitor sorafenib in patients with pulmonary arterial hypertension. | Clin Pharmacol Ther | 2010 | https://conductscience.org/library/papers/20010555 | PubMed |
| 11 | 21378262 | Tyrosine kinase inhibitors are potent acute pulmonary vasodilators in rats. | Am J Respir Cell Mol Biol | 2011 | https://conductscience.org/library/papers/21378262 | PubMed |
| 12 | 26284693 | Clinical features of pulmonary arterial hypertension in patients receiving dasatinib. | Am J Hematol | 2015 | https://conductscience.org/library/papers/26284693 | PubMed |
| 13 | 32417272 | Pulmonary arterial hypertension specific therapy: The old and the new. | Pharmacol Ther | 2020 | https://conductscience.org/library/papers/32417272 | PubMed |
| 14 | 25902888 | Delivery of imatinib-incorporated nanoparticles into lungs suppresses the development of monocrotaline-induced pulmonary arterial hypertension. | Int Heart J | 2015 | https://conductscience.org/library/papers/25902888 | PubMed |
| 15 | 26070575 | Inhaled Therapies for Pulmonary Hypertension. | Respir Care | 2015 | https://conductscience.org/library/papers/26070575 | PubMed |
| 16 | 21376411 | Pro-apoptotic effects of imatinib on PDGF-stimulated pulmonary artery smooth muscle cells from patients with idiopathic pulmonary arterial hypertension. | Int J Cardiol | 2012 | https://conductscience.org/library/papers/21376411 | PubMed |
| 17 | 31813986 | Chronic inflammation within the vascular wall in pulmonary arterial hypertension: more than a spectator. | Cardiovasc Res | 2020 | https://conductscience.org/library/papers/31813986 | PubMed |
| 18 | 8548747 | Inhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative. | Cancer Res | 1996 | https://conductscience.org/library/papers/8548747 | PubMed |
| 19 | 22037378 | Comprehensive analysis of kinase inhibitor selectivity. | Nat Biotechnol | 2011 | https://conductscience.org/library/papers/22037378 | PubMed |
| 20 | 20581169 | Imatinib in pulmonary arterial hypertension patients with inadequate response to established therapy. | Am J Respir Crit Care Med | 2010 | https://conductscience.org/library/papers/20581169 | PubMed |
Cited by12
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 24 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 41949976 | Advances in Novel Therapeutic Strategies for Pulmonary Arterial Hypertension. | Can Respir J | 2026 | https://conductscience.org/library/papers/41949976 | PubMed |
| 40728162 | Novel Insights Into Receptor Tyrosine Kinases in Pulmonary Arterial Hypertension. | J Am Heart Assoc | 2025 | https://conductscience.org/library/papers/40728162 | PubMed |
| 40722843 | State of the Art in Pulmonary Arterial Hypertension: Molecular Basis, Imaging Modalities, and Right Heart Failure Treatment. | Biomedicines | 2025 | https://conductscience.org/library/papers/40722843 | PubMed |
| 40437342 | Clinical Pharmacokinetics of Inhaled Drugs for Pulmonary Hypertension. | Clin Pharmacokinet | 2025 | https://conductscience.org/library/papers/40437342 | PubMed |
| 40410529 | Cardiovascular inhalation for targeted drug delivery in cardiac disease. | Heart Fail Rev | 2025 | https://conductscience.org/library/papers/40410529 | PubMed |
| 40371062 | Sudden cardiac death in congenital heart disease-a narrative review and update. | Front Cardiovasc Med | 2025 | https://conductscience.org/library/papers/40371062 | PubMed |
| 39684570 | Searching for Old and New Small-Molecule Protein Kinase Inhibitors as Effective Treatments in Pulmonary Hypertension-A Systematic Review. | Int J Mol Sci | 2024 | https://conductscience.org/library/papers/39684570 | PubMed |
| 39112561 | Mechanisms and treatment of pulmonary arterial hypertension. | Nat Rev Cardiol | 2025 | https://conductscience.org/library/papers/39112561 | PubMed |
| 38532768 | IMPAHCT: A randomized phase 2b/3 study of inhaled imatinib for pulmonary arterial hypertension. | Pulm Circ | 2024 | https://conductscience.org/library/papers/38532768 | PubMed |
| 38495664 | Pulmonary Hypertension in Women. | Methodist Debakey Cardiovasc J | 2024 | https://conductscience.org/library/papers/38495664 | PubMed |
| 37628831 | Pharmacology and Rationale for Seralutinib in the Treatment of Pulmonary Arterial Hypertension. | Int J Mol Sci | 2023 | https://conductscience.org/library/papers/37628831 | PubMed |
| 37486563 | Medical Management of Right Ventricular Dysfunction in Pulmonary Arterial Hypertension. | Curr Heart Fail Rep | 2023 | https://conductscience.org/library/papers/37486563 | PubMed |
Genes5
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| EGF | 1950 | PubTator's text mining | https://conductscience.org/library/genes/1950 | NCBI Gene |
| FGF2 | 2247 | PubTator's text mining | https://conductscience.org/library/genes/2247 | NCBI Gene |
| KIT | 3815 | PubTator's text mining | https://conductscience.org/library/genes/3815 | NCBI Gene |
| SRC | 6714 | PubTator's text mining | https://conductscience.org/library/genes/6714 | NCBI Gene |
| VEGFA | 7422 | PubTator's text mining | https://conductscience.org/library/genes/7422 | NCBI Gene |
Drugs1
The drugs whose trials, in the Pipelines release, list the paper.
| Drug | ChEMBL ID | The trials list it as | Trials | In Drugs and targets |
|---|---|---|---|---|
| IMATINIB | CHEMBL941 | Derived from the trial | 1 | https://conductscience.org/library/drugs/CHEMBL941 |
Source ChEMBL
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Comments and corrections
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/36923571
GET https://conductscience.org/api/papers/v1/36923571/references?page=2